|
1
|
Rubin MA, Kleter B, Zhou M, Ayala G,
Cubilla AL, Quint WG and Pirog EC: Detection and typing of human
papillomavirus DNA in penile carcinoma: evidence for multiple
independent pathways of penile carcinogenesis. Am J Pathol.
159:1211–1218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wabinga HR, Parkin DM, Wabwire-Mangen F
and Nambooze S: Trends in cancer incidence in Kyadondo County,
Uganda, 1960–1997. Br J Cancer. 82:1585–1592. 2000.PubMed/NCBI
|
|
3
|
Greenberg RE: Surgical management of
carcinoma of the penis. Urol Clin North Am. 37:369–378. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bleeker MC, Heideman DA, Snijders PJ,
Horenblas S, Dillner J and Meijer CJ: Penile cancer: Epidemiology,
pathogenesis and prevention. World J Urol. 27:141–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Broders AC: Squamous-cell epithelioma of
the skin: A study of 256 cases. Ann Surg. 73:141–160. 1921.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Verhoeven RH, Janssen-Heijnen ML, Saum KU,
Zanetti R, Caldarella A, Holleczek B, Brewster DH, Hakulinen T,
Horenblas S, Brenner H, et al: Population-based survival of penile
cancer patients in Europe and the United States of America: No
improvement since 1990. Eur J Cancer. 49:1414–1421. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rodney S, Feber A, Arya M and Muneer A:
Molecular markers in penile cancer. Curr Probl Cancer. 39:137–145.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bizet AA, Tran-Khanh N, Saksena A, Liu K,
Buschmann MD and Philip A: CD109-mediated degradation of TGF-beta
receptors and inhibition of TGF-β responses involve regulation of
SMAD7 and Smurf2 localization and function. J Cell Biochem.
113:238–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin M, Sutherland DR, Horsfall W, Totty N,
Yeo E, Nayar R, Wu XF and Schuh AC: Cell surface antigen CD109 is a
novel member of the alpha(2) macroglobulin/C3, C4, C5 family of
thioester-containing proteins. Blood. 99:1683–1691. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tam BY, Finnson KW and Philip A:
Glycosylphosphatidylinositol-anchored proteins regulate
transforming growth factor-beta signaling in human keratinocytes. J
Biol Chem. 278:49610–49617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hagiwara S, Murakumo Y, Mii S, Shigetomi
T, Yamamoto N, Furue H, Ueda M and Takahashi M: Processing of CD109
by furin and its role in the regulation of TGF-beta signaling.
Oncogene. 29:2181–2191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Litvinov IV, Bizet AA, Binamer Y, Jones
DA, Sasseville D and Philip A: CD109 release from the cell surface
in human keratinocytes regulates TGF-β receptor expression, TGF-β
signalling and STAT3 activation: Relevance to psoriasis. Exp
Dermatol. 20:627–632. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hashimoto M, Ichihara M, Watanabe T, Kawai
K, Koshikawa K, Yuasa N, Takahashi T, Yatabe Y, Murakumo Y, Zhang
JM, et al: Expression of CD109 in human cancer. Oncogene.
23:3716–3720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang JM, Hashimoto M, Kawai K, Murakumo
Y, Sato T, Ichihara M, Nakamura S and Takahashi M: CD109 expression
in squamous cell carcinoma of the uterine cervix. Pathol Int.
55:165–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sato T, Murakumo Y, Hagiwara S, Jijiwa M,
Suzuki C, Yatabe Y and Takahashi M: High-level expression of CD109
is frequently detected in lung squamous cell carcinomas. Pathol
Int. 57:719–724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong F, Liu F, Yan S, Liu X, Jiang Z and
Liu J: Elevated expression of CD109 in esophageal squamous cell
carcinoma. Pathol Oncol Res. 21:1273–1275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong F, Wang Y, Li L, Wang Y, Liu X and
Liu J: CD109 expression is increased in cutaneous squamous cell
carcinoma. J Dermatol. 41:947–949. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong F, Lu C, Chen X, Guo Y and Liu J:
CD109 is a novel marker for squamous cell/adenosquamous carcinomas
of the gallbladder. Diagn Pathol. 10:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong F, Wang Y, Li L, Liu X, Yan S and Liu
J: CD109 is expressed in epithelial cells of the juvenile thymus.
Histopathology. 66:1041–1044. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hagiwara S, Murakumo Y, Sato T, Shigetomi
T, Mitsudo K, Tohnai I, Ueda M and Takahashi M: Up-regulation of
CD109 expression is associated with carcinogenesis of the squamous
epithelium of the oral cavity. Cancer Sci. 99:1916–1923.
2008.PubMed/NCBI
|
|
22
|
Ye BG, Sun HC, Zhu XD, Chai ZT, Zhang YY,
Ao JY, Cai H, Ma DN, Wang CH, Qin CD, et al: Reduced expression of
CD109 in tumor-associated endothelial cells promotes tumor
progression by paracrine interleukin-8 in hepatocellular carcinoma.
Oncotarget. 7:29333–29345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong F, Cheng Y, Sun Q, Lu W, Zhang G, Li
L, Allen TD and Liu J: CD109 is specifically expressed in
endothelial cells of cutaneous cavernous haemangioma.
Histopathology. 67:133–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cuppini L, Calleri A, Bruzzone MG, Prodi
E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL,
Ceroni M, et al: Prognostic value of CD109+ circulating endothelial
cells in recurrent glioblastomas treated with bevacizumab and
irinotecan. PLoS One. 8:e743452013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mancuso P, Calleri A, Gregato G, Labanca
V, Quarna J, Antoniotti P, Cuppini L, Finocchiaro G, Eoli M, Rosti
V and Bertolini F: A subpopulation of circulating endothelial cells
express CD109 and is enriched in the blood of cancer patients. PLoS
One. 9:e1147132014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bizet AA, Liu K, Tran-Khanh N, Saksena A,
Vorstenbosch J, Finnson KW, Buschmann MD and Philip A: The TGF-β
co-receptor, CD109, promotes internalization and degradation of
TGF-β receptors. Biochim Biophys Acta. 1813:742–753. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vorstenbosch J, Gallant-Behm C, Trzeciak
A, Roy S, Mustoe T and Philip A: Transgenic mice overexpressing
CD109 in the epidermis display decreased inflammation and
granulation tissue and improved collagen architecture during wound
healing. Wound Repair Regen. 21:235–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vorstenbosch J, Al-Ajmi H, Winocour S,
Trzeciak A, Lessard L and Philip A: CD109 overexpression
ameliorates skin fibrosis in a mouse model of bleomycin-induced
scleroderma. Arthritis Rheum. 65:1378–1383. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hockla A, Radisky DC and Radisky ES:
Mesotrypsin promotes malignant growth of breast cancer cells
through shedding of CD109. Breast Cancer Res Treat. 124:27–38.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arteaga CL: Inhibition of TGFbeta
signaling in cancer therapy. Curr Opin Genet Dev. 16:30–37. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bierie B and Moses HL: Tumour
microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer.
Nat Rev Cancer. 6:506–520. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Matsuzaki K and Okazaki K: Transforming
growth factor-beta during carcinogenesis: The shift from epithelial
to mesenchymal signaling. J Gastroenterol. 41:295–303. 2006.
View Article : Google Scholar : PubMed/NCBI
|
